TY - JOUR
T1 - The Effect of Cumulative Anticholinergic Use on the Cognitive Function of Older Adults
T2 - Results from the Personality and Total Health (PATH) through Life Study
AU - Neelamegam, Malinee
AU - Zgibor, Janice
AU - Chen, Henian
AU - O'Rourke, Kathleen
AU - Bakour, Chighaf
AU - Rajaram, Lakshminarayan
AU - Anstey, Kaarin J.
AU - Newman, Anne
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved.
PY - 2020/6/5
Y1 - 2020/6/5
N2 - Background: Multiple comorbidities are common in older adults, resulting in polypharmacy that often includes medications with anticholinergic properties. These medications have multiple side effects, which are more pronounced in the older population. This study examined the association between the use of anticholinergics and changes in the cognitive function of older adults. Methods: The study population consisted of 2,222 individuals aged 65-69 years at baseline from the Personality and Total Health (PATH) Through Life Study in Australia. Medication data were obtained from the Pharmaceutical Benefits Scheme (PBS). Cognitive measures were obtained from neuropsychological battery assessment. Exposure to cumulative anticholinergic use was quantified to a total standardized daily dose (TSDD). The association between change in cognitive measures between baseline and 4-year follow-up, and cumulative use of anticholinergic was assessed through generalized linear models. Results: During the study period, 18.6% (n = 413) of participants filled at least one prescription for anticholinergics. Compared to those not on anticholinergics, participants on anticholinergics were more likely to be woman (62.7% compared to 45.1%) and spent lesser time engaging in vigorous physical activity (0.4 h/week compared to 0.9 h/week). Cumulative use of anticholinergic resulting in a TSDD exceeding 1,095 was significantly associated with poorer performance in Trail Making Test Part B (Model 1: ß = 5.77, Model 2: ß = 5.33, Model 3: ß = 8.32, p <. 01), indicating impairment in processing speed. Conclusions: In our study, except for speed of processing, other cognitive domains measured were not affected by cumulative anticholinergic use over a 4-year period.
AB - Background: Multiple comorbidities are common in older adults, resulting in polypharmacy that often includes medications with anticholinergic properties. These medications have multiple side effects, which are more pronounced in the older population. This study examined the association between the use of anticholinergics and changes in the cognitive function of older adults. Methods: The study population consisted of 2,222 individuals aged 65-69 years at baseline from the Personality and Total Health (PATH) Through Life Study in Australia. Medication data were obtained from the Pharmaceutical Benefits Scheme (PBS). Cognitive measures were obtained from neuropsychological battery assessment. Exposure to cumulative anticholinergic use was quantified to a total standardized daily dose (TSDD). The association between change in cognitive measures between baseline and 4-year follow-up, and cumulative use of anticholinergic was assessed through generalized linear models. Results: During the study period, 18.6% (n = 413) of participants filled at least one prescription for anticholinergics. Compared to those not on anticholinergics, participants on anticholinergics were more likely to be woman (62.7% compared to 45.1%) and spent lesser time engaging in vigorous physical activity (0.4 h/week compared to 0.9 h/week). Cumulative use of anticholinergic resulting in a TSDD exceeding 1,095 was significantly associated with poorer performance in Trail Making Test Part B (Model 1: ß = 5.77, Model 2: ß = 5.33, Model 3: ß = 8.32, p <. 01), indicating impairment in processing speed. Conclusions: In our study, except for speed of processing, other cognitive domains measured were not affected by cumulative anticholinergic use over a 4-year period.
KW - Cognition
KW - Cognitive aging
KW - Medication
UR - http://www.scopus.com/inward/record.url?scp=85091191241&partnerID=8YFLogxK
U2 - 10.1093/gerona/glaa145
DO - 10.1093/gerona/glaa145
M3 - Article
SN - 1079-5006
VL - 75
SP - 1706
EP - 1714
JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
IS - 9
ER -